M43 / Celon Pharma - LARVOL DELTA

Exploring the mechanism behind the novel FGF1 analogue in treating metabolic syndrome-related conditions in db/db mouse model (EASD 2024) - "M43 significantly improved glycemic control, biochemistry parameters and liver histological alterations in db/db mice model. Our findings identified genes and pathways involved in beneficial action of M43 in the liver giving new insight in understanding M43 action."

Preclinical • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus • FABP1 • FABP5 • FGF1 • FGFR